Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | AKT2 | P31751 | 1/20 | 0.59 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980346 | 1.00 | NT5E (0.59) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL21412037 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL30729419 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL31012657 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL30729416 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL23291077 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Hydrochloric Acid SCHEMBL18956189 | 0.98 | NT5E (0.58) | NT5EAKT1AKT2METAP2HSD17B1 | |
| Trifluoroacetic Acid SCHEMBL30557149 | 0.86 | NT5E (0.49) | NT5EAKT1AKT2METAP2HSD17B1 | |
| SCHEMBL30424015 | 0.86 | AKT2 (0.71) | NT5EAKT1AKT2RPS6KA3CHEK1 | |
| Phenol SCHEMBL27544955 | 0.82 | AKT2 (0.80) | NT5EAKT1AKT2RPS6KA3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805280-B | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-12-06 | — | — | CN | claimed |
| CN-113717154-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-11-15 | — | — | CN | claimed |
| CN-112203653-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-08-16 | — | — | CN | claimed |
| CN-110946865-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | claimed |
| CN-114007612-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | claimed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3848035-B1 | 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024186892-A2 | REGULATED CONTROL OF RNA INTERFERENCE BY ALTERNATIVE SPLICING | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111194215-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-111499615-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11434489-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-114269922-A | Methods for modulating splicing | 斯基霍克疗法公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114007612-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007614-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | NT5E 2746/4885AKT1 1807/4885AKT2 1653/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | NT5E 2746/4885AKT1 1807/4885AKT2 1653/4885 |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | HTT, HYPK, HDAC6 | NT5E 2750/4885AKT1 3356/4885AKT2 3450/4885 |
| US-11434489-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | NT5E 2746/4885AKT1 1807/4885AKT2 1653/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | NT5E 1016/4885AKT1 2837/4885AKT2 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.